Zobrazeno 1 - 10
of 241
pro vyhledávání: ''
Autor:
Andrea De Giglio, Valeria Grandinetti, Marta Aprile, Greta Borelli, Anita Campus, Anna Laura Croci Chiocchini, Marco Busutti, Gisella Vischini, Alessandro Di Federico, Francesca Sperandi, Barbara Melotti, Andrea Ardizzoni, Gaetano La Manna, Francesco Gelsomino
Publikováno v:
Lung Cancer. 174:91-96
The combination of immune-checkpoint inhibitors (ICI) and platinum-pemetrexed chemotherapy (CT) in first-line setting improved survival outcomes of advanced non-small cell lung cancer (NSCLC) patients. Among the various adverse events, renal toxicity
Autor:
Alexis B. Cortot, Didier Debieuvre, L. Moreau, Radj Gervais, Jacques Margery, Julien Mazieres, Olivier Molinier, Michel Poudenx, Alexandra Langlais, Nicolas Girard, Patrick Dumont, Gérard Zalcman, Franck Morin, Virginie Westeel, Pierre-Jean Souquet, Eric Pichon, Fabrice Barlesi, Maurice Pérol, Jérôme Dauba, Jacques Cadranel, Clarisse Audigier-Valette, Denis Moro-Sibilot
Publikováno v:
Lung Cancer. 164:84-90
Benefit from maintenance in advanced non-squamous non-small cell lung cancer (NS-NSCLC) might favor switch maintenance after disease stabilization (SD) and continuation after objective response (OR). This trial assessed a maintenance strategy conditi
Autor:
Nicolas Girard, Gaëtane Simon, Maurice Pérol, Thomas Filleron, Christos Chouaid, Roland Schott, Matthieu Carton, Clarisse Audigier Valette, Mathieu Robain, Xavier Quantin, Didier Debieuvre, Radj Gervais, Hervé Lena, Bruno Coudert
Publikováno v:
Lung Cancer. 162:119-127
Background Cisplatin-based chemotherapy administered concurrently to thoracic radiation therapy is the recommended treatment for fit patients with unresectable stage III NSCLC. The aim of this study was to describe patient profiles and clinical outco
Autor:
Anas Gazzah, Pilar Garrido, Alexis B. Cortot, Jaafar Bennouna, Melissa Lynne Johnson, Maciej Gil, Haruyasu Murakami, Benjamin Besse
Publikováno v:
Lung Cancer. 142:63-69
Objectives Efficacy and safety of necitumumab when combined with pembrolizumab was assessed in patients with Stage IV non-small cell lung cancer (NSCLC) of squamous and nonsquamous histology, who had progressed after treatment with a platinum-based d
Autor:
Takashi Seto, Noboru Yamamoto, Takeharu Yamanaka, Yuichiro Ohe, Makoto Nishio, Tatsuya Yoshida, Toyoaki Hida, Akira Ono, Takayasu Kurata, Kentaro Sakamaki, Hiroaki Okamoto, Miyako Satouchi, Seiji Niho, Koichi Goto, Tetsuo Akimoto
Publikováno v:
Lung Cancer. 141:64-71
Objectives SPECTRA is a multicenter, randomized phase II study of chemotherapy with cisplatin (CDDP) plus S-1 versus CDDP plus pemetrexed (PEM) in combination with thoracic radiotherapy (TRT) for locally advanced non-squamous non-small cell lung canc
Autor:
Alvin Soon Tiong Lim, Quan Sing Ng, Anantham Devanand, Daniel S.W. Tan, T. Rajasekaran, Eng Huat Tan, Zaw Win Aung, Chee Keong Toh, G. Lai, Chow Wei Too, Tony Kiat-Hon Lim, Aaron C. Tan, Bien Soo Tan, Tina P.T. Koh, Tse Hui Lim, Mei-Kim Ang, Angela Takano, Wan Ling Tan, Shou Yu Poon, Brett Doble, Apoorva Gogna, Amit Jain, Boon-Hean Ong, Ravindran Kanesvaran, Wan-Teck Lim, Gek San Tan
Publikováno v:
Lung Cancer. 139:207-215
Objectives There is an expanding list of therapeutically relevant biomarkers for non-small cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition in scaling traditional single biomarker assays from small biopsie
Autor:
Masaru Suzuki, Satoshi Oizumi, Eiki Kikuchi, Kenya Kanazawa, Hisashi Tanaka, Kaoruko Shimizu, Hiroshi Yokouchi, Ryoichi Honda, Toshiyuki Harada, Hajime Asahina, Tomoo Ikari, Kei Takamura, Tetsuya Kojima, Masao Harada, Yuka Fujita, Hiroshi Isobe, Hirotoshi Dosaka-Akita, Takahiro Ogi, Masaharu Nishimura, Fumiko Sugaya, Satoshi Konno
Publikováno v:
Lung cancer. 138:65-71
Objectives Patients with concomitant advanced non-small cell lung cancer (NSCLC) and interstitial lung disease (ILD) are excluded from most clinical chemotherapy trials because of the high risk of exacerbating the latter condition. This study prospec
Autor:
Primo N. Lara, M. Phillip DeYoung, Xiaowei Wang, Sergey Orlov, Enriqueta Felip, James Vasquez, Katherine Baker-Neblett, Manuel Domine, Nina Karaseva, Ulrik Lassen, Li Yan, Daniel Morgensztern, Pilar Garrido, Jose Manuel Trigo, Paul K. Paik, Marina Shomova, Ionel Mitrica, Ignacio Delgado, Olga Burdaeva
Publikováno v:
Lung Cancer. 136:74-79
Objectives GSK3052230 (FP-1039) is a soluble fusion protein that acts as ligand trap sequestering fibroblast growth factors (FGFs) involved in tumor growth and angiogenesis, while sparing the hormonal FGFs. Because of this selectivity, the molecule i
Autor:
Konstantinos N. Syrigos, Mark A. Socinski, Wei Zhang, Dimitrios Mavroudis, Liza C. Villaruz, Jong Seok Kim, Manuel Cobo
Publikováno v:
Lung Cancer. 136:52-56
Objectives Necitumumab is a second-generation, recombinant, human IgG1-type monoclonal antibody directed against EGFR approved for adult patients with metastatic squamous non-small cell lung cancer (NSCLC) in combination with gemcitabine and cisplati
Autor:
Santiago Viteri, Santiago Ramón y Cajal, José Ignacio Toscas, Irene Moya-Horno, José Antonio Maestre-Alcácer, Rafael Rosell, Laura Romero-Vielva
Publikováno v:
Lung Cancer. 133:117-122
Introduction Despite all treatment advances, lung cancer is still the main cause of death worldwide. Treatment for resectable stage IIIA remains controversial including definitive chemoradiotherapy and induction treatment followed by surgery. After d